The Advanced Interventions in Mood Disorders (AIM) Clinic provides adults with severe mood disorders access to novel treatments and innovative research projects.
Depressive disorders are common mental health conditions, affecting about one in 12 Australians.
While there are evidence-based treatments for depressive disorders, approximately one-third of people do not experience a significant or sustained improvement in their symptoms using these first-line treatments.
The AIM Clinic provides novel treatments and conducts innovative research projects that aim to reduce depressive symptoms and improve quality of life in people with difficult-to-treat mood disorders.
Treatments available
Ketamine Treatment Service
The AIM Clinic is currently providing a 3-week course of low-dose intravenous ketamine treatment for eligible adults with difficult-to-treat depression who are currently receiving treatment at the Royal Melbourne Hospital (RMH) or Western Health mental health services.
Learn more about the ketamine treatment service.
Research projects
Hearts and Minds: does metformin or atorvastatin help to treat depression?
Hearts and Minds is a clinical trial to investigate whether metformin or atorvastatin help to reduce symptoms of depression.
Neural mechanisms of ketamine antidepressant treatment (NeuroKet)
NeuroKet is a neuroimaging study that aims to understand how ketamine works as an antidepressant medication.
Psychedelic-assisted therapy for depression
A new clinical trial is examining the efficacy and safety of a new psychedelic-assisted therapy for treatment-resistant depression.
SKY-D (Study of Ketamine for Youth Depression)
SKY-D was a clinical trial investigating whether ketamine is an effective treatment for young people aged 16 to 25 years with moderate-to-severe depression.